Suppr超能文献

鉴定激活CD4+和CD8+ T细胞反应的突变型ras癌基因肽中的重叠表位。

Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.

作者信息

Abrams S I, Stanziale S F, Lunin S D, Zaremba S, Schlom J

机构信息

Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, MD 20892-1750, USA.

出版信息

Eur J Immunol. 1996 Feb;26(2):435-43. doi: 10.1002/eji.1830260225.

Abstract

Mutant ras p21 proteins contain sequences which distinguish them from normal endogenous ras and, thus, may represent unique epitopes for T cell recognition of antigen bearing tumor cells. Here, we examined the capacity of a mutant K-ras 9-mer peptide to induce in vivo CD8+ cytotoxic T lymphocytes (CTL). The peptide chosen reflected positions 4-12 of the point-mutated sequence of the K-ras oncogene encoding the Gly to Val substitution at codon 12. The overall rationale for selecting this particular 9-mer sequence was threefold: the mutant peptide contained a putative major histocompatibility complex (MHC) class I consensus anchor motif for murine H-2Kd; specific binding to MHC class I may then create an immunogenic complex for the induction of anti-ras CD8+ CTL; and finally, the mutant sequence overlapped with a newly characterized anti-ras CD4+ T helper type 1 epitope, which may have implications for the coordination and activation of both anti-ras immune mechanisms against the same target cell antigenic determinant. A functional interaction with H-2Kd was demonstrated with the mutant ras4-12(V12) peptide, but not the normal ras4-12(G12) peptide, which specifically inhibited an H-2Kd-restricted, anti-nucleoprotein NP147-155 CTL response in a dose-dependent fashion. An anti-ras CD8+ T cell line was then established from immune splenocytes of BALB/c (H-2d) mice injected with ras4-12 (V12) in adjuvant, which mediated peptide-specific lysis of syngeneic P815 tumor targets. Cytotoxicity was restricted by H-2Kd and strongly specific for the mutant ras peptide. Importantly, these anti-ras CTL specifically lysed a syngeneic tumor line (i.e. A20 lymphoma) transduced with the corresponding point-mutated ras oncogene, suggesting T cell receptor recognition of endogenously derived antigen. Overall, these data demonstrated that mutant ras p21 at codon 12(Gly-->Val) contained a peptide sequence which exhibited specific functional binding to a murine MHC class I molecule; the ability of the mutant, but not the normal sequence to bind selectively to murine MHC class I likely reflected the generation of a C-terminal anchor residue; and the ras4-12(V12) peptide was immunogenic for the production of antigen-specific CD8+ CTL, which lysed in vitro a syngeneic tumor cell line harboring the mutant K-ras oncogene.

摘要

突变型ras p21蛋白含有使其区别于正常内源性ras的序列,因此可能代表T细胞识别携带抗原的肿瘤细胞的独特表位。在此,我们检测了一种突变型K-ras 9肽诱导体内CD8+细胞毒性T淋巴细胞(CTL)的能力。所选择的肽反映了K-ras癌基因点突变序列的第4至12位,该突变在第12密码子处编码甘氨酸至缬氨酸的替换。选择这个特定9肽序列的总体理由有三点:突变肽含有针对小鼠H-2Kd的假定主要组织相容性复合体(MHC)I类共有锚定基序;与MHC I类的特异性结合可能会形成一种免疫原性复合物,用于诱导抗ras CD8+ CTL;最后,突变序列与一个新鉴定的抗ras CD4+ 1型辅助性T细胞表位重叠,这可能对针对同一靶细胞抗原决定簇的两种抗ras免疫机制的协调和激活有影响。突变型ras4-12(V12)肽与H-2Kd存在功能性相互作用,而正常的ras4-12(G12)肽则没有,突变型ras4-12(V12)肽以剂量依赖性方式特异性抑制H-2Kd限制性的抗核蛋白NP147-155 CTL反应。然后从注射了佐剂中ras4-12(V12)的BALB/c(H-2d)小鼠的免疫脾细胞中建立了抗ras CD8+ T细胞系,该细胞系介导了对同基因P815肿瘤靶标的肽特异性裂解。细胞毒性受H-2Kd限制,且对突变型ras肽具有高度特异性。重要的是,这些抗ras CTL特异性裂解了用相应点突变ras癌基因转导的同基因肿瘤系(即A-20淋巴瘤),表明T细胞受体识别内源性衍生抗原。总体而言,这些数据表明,第12密码子(甘氨酸→缬氨酸)处的突变型ras p21含有一个肽序列,该序列与小鼠MHC I类分子表现出特异性功能结合;突变序列而非正常序列选择性结合小鼠MHC I类的能力可能反映了C末端锚定残基的产生;并且ras4-12(V12)肽具有免疫原性,可产生抗原特异性CD8+ CTL,其在体外裂解了携带突变型K-ras癌基因的同基因肿瘤细胞系。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验